Evidence map›Paper›PMID 34683944›Full record

ArticlePharmaceutics2021

Evaluation of the Targeting and Therapeutic Efficiency of Anti-EGFR Functionalised Nanoparticles in Head and Neck Cancer Cells for Use in NIR-II Optical Window.

Teklu Egnuni, Nicola Ingram, Ibrahim Mirza, P Louise Coletta, James R McLaughlan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Teklu EgnuniLeeds Institute of Medical Research, University of Leeds, St. James's University Hospital, Leeds LS9 7TF, UK.ORCID 0000-0001-8714-0687
Nicola IngramLeeds Institute of Medical Research, University of Leeds, St. James's University Hospital, Leeds LS9 7TF, UK.ORCID 0000-0001-5274-8502
Ibrahim MirzaSchool of Electronic and Electrical Engineering, University of Leeds, Leeds LS2 9JT, UK.
P Louise ColettaLeeds Institute of Medical Research, University of Leeds, St. James's University Hospital, Leeds LS9 7TF, UK.
James R McLaughlanLeeds Institute of Medical Research, University of Leeds, St. James's University Hospital, Leeds LS9 7TF, UK.ORCID 0000-0001-5795-4372
University of Leeds · GB

Funding

EPSRC EP/S001069/1
6 · The paper itself

Abstract

Gold nanoparticles have been indicated for use in a diagnostic and/or therapeutic role in several cancer types. The use of gold nanorods (AuNRs) with a surface plasmon resonance (SPR) in the second near-infrared II (NIR-II) optical window promises deeper anatomical penetration through increased maximum permissible exposure and lower optical attenuation. In this study, the targeting and therapeutic efficiency of anti-epidermal growth factor receptor (EGFR)-antibody-functionalised AuNRs with an SPR at 1064 nm was evaluated in vitro. Four cell lines, KYSE-30, CAL-27, Hep-G2 and MCF-7, which either over- or under-expressed EGFR, were used once confirmed by flow cytometry and immunofluorescence. Optical microscopy demonstrated a significant difference (

Indexed as

EGFRgold nanorodsHNSCCNIR-II windowPTTtargetinguptake

Identifiers

PMID34683944
PMCPMC8537270
OpenAlexW3206758027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.